ReviewNature reviews. Endocrinology2025
Management, biomarkers and prognosis in people developing endocrinopathies associated with immune checkpoint inhibitors.
Review in Nature reviews. Endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Real world incidence, predictors and outcomes of endocrine immune-related adverse events following immune checkpoint inhibitors.Human vaccines & immunotherapeutics · 2026Article
- Review
- Long-term imaging characteristics of the pancreas related to diabetes induced by immune checkpoint inhibitor therapy.Acta diabetologica · 2026Article
- The Impact of Angiotensin-Converting Enzyme Inhibitors on Immune-Related Adverse Events and Clinical Outcomes in Patients with Metastatic NSCLC.Biomedicines · 2026Article
- Hyperglycemia during ICI Therapy: etiology, risk factors, and survival outcome.Journal of endocrinological investigation · 2026Article
- Baseline TSH within reference range and incident thyroid dysfunction in cancer patients: a retrospective cohort study.Hormones (Athens, Greece) · 2026Article
- Local, but not circulating, complement C3 shapes immune checkpoint blockade efficacy by controlling myeloid cell infiltration.Nature communications · 2026Article
- Endocrine dysfunction induced by anti-PD-1 antibody and tyrosine kinase inhibitor in a pediatric patient with renal cell carcinoma.Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2026Article
- Review
- Integration Analysis of Bayesian and Machine Learning for Heterogeneity, Biomarkers, and Optimal Combination Regimens of Pucotenlimab in Solid Tumors.Cancer medicine · 2026Article
- An update on hypophysitis.Nature reviews. Endocrinology · 2026Review
- Immunotherapy in Thyroid Cancer: Current Strategies and Challenges.Cancer medicine · 2026Review
- Redefining Dendritic Cell Vaccines: Synergistically Co-priming DC and B Cells With Nanoparticles Loading Whole Cell Antigens Maximizes the Efficacy of DC Vaccines.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Rhabdomyolysis in a patient with lung cancer with sintilimab-induced overlap syndrome and hypothyroidism: A case report.Experimental and therapeutic medicine · 2026Article
- Transient adrenocorticotropic hormone elevation with a disproportionate cortisol response prior to the onset of immune checkpoint inhibitor-related hypophysitis.Hormones (Athens, Greece) · 2026Review
- Immune checkpoint inhibitor-related endocrinopathies: from immune crosstalk to predictive biomarkers and precision management.Frontiers in endocrinology · 2026Review
- The toxicity profile and temporal dynamics of dual PD-1/CTLA-4 immune checkpoint blockade: a real-world pharmacovigilance study using the FAERS database.Frontiers in immunology · 2026Article
- Real-world insights into incidence and risk factors of thyroid dysfunction following immune checkpoint inhibitor therapy.Frontiers in immunology · 2026Observational
- Case Report: Successful rechallenge of cadonilimab-induced cystitis, adrenal insufficiency, and diabetic ketoacidosis in a patient with metastatic gastric-type endocervical adenocarcinoma.Frontiers in oncology · 2026Article
- Dominant T cell receptor clonotypes in adrenocorticotropic hormone-secreting pituitary carcinoma are the highest-frequency clones among CD4Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune-related adverse events (irAEs), including endocrine irAEs, can occur in response to cancer immunotherapy using immune checkpoint inhibitors (ICIs). Of the endocrine irAEs, pituitary and thyroid irAEs are most frequently observed, followed by primary adrenal insufficiency, type 1 diabetes mellitus and hypoparathyroidism. Notably, pituitary irAEs and type 1 diabetes mellitus can be lethal if overlooked, potentially leading to adrenal crisis and diabetic ketoacidosis, respectively. On the other hand, pituitary and thyroid irAEs are reported to be associated with more favourable prognoses in some cancers if treated appropriately with hormone-replacement therapies. It would be useful to identify those people who are likely to develop endocrine irAEs before initiating therapy with ICIs. Anti-pituitary antibodies and thyroid autoantibodies have been identified as potential biomarkers for the development of pituitary and thyroid irAEs, respectively. This Review elaborates on the clinical characteristics and management strategies of several endocrine irAEs, using the latest research findings and guidelines published by several academic societies.
Indexed as
Identifiers
39779950What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.